



CERTIFICATE OF COMPLETION

THE UNIVERSITY OF WASHINGTON AND NATIONAL HIV CURRICULUM CERTIFY THAT

Justin Hooks, MSN

HAS COMPLETED THE FOLLOWING LESSONS IN THE

KEY POPULATIONS 3RD EDITION MODULE

HIV in Infants and Children, HIV in Adolescents and Young Adults, HIV in Women, HIV in Older Adults,
HIV and Corrections, and HIV-2 Infection

A handwritten signature in black ink, reading "David Spach, MD".

David H. Spach, MD
Editor-in-Chief, National HIV Curriculum
Professor of Medicine, University of Washington

This certificate shows the progress of **Justin Hooks, MSN**, a Nurse Practitioner, identified by **justin.hooks02@gmail.com** as of June 1, 2025, 11:28 pm. You may validate this certificate or obtain a digital copy by visiting <https://www.hiv.uw.edu/certificate/key-populations/justin.hooks02@gmail.com/3>

The following Lessons were completed along with their quizzes with a quiz score of 80% or higher:

| Lessons | Learning Objectives |
|--|--|
| HIV in Infants and Children Completed April 22, 2024 | <ul style="list-style-type: none"> • Discuss basic epidemiologic features of perinatally-acquired HIV and pediatric HIV in the United States • Explain the timing and types of diagnostic tests used to diagnose HIV in infants less than 1 year of age and in older children • List symptoms and classification of HIV in children using the most recent CDC surveillance case definition for pediatric HIV • Summarize antiretroviral therapy management in children, including initiation, adverse effects, and approach to virologic failure • Discuss opportunistic infection prevention recommendations for infants and children and how these recommendations are influenced by a child's age and stage of HIV |
| HIV in Adolescents and Young Adults Completed April 23, 2024 | <ul style="list-style-type: none"> • Explain current epidemiologic features of HIV in adolescents and young adults in the United States • Discuss factors that increase the risk of adolescents and young adults acquiring HIV • List appropriate antiretroviral regimens for adolescents and young adults • Summarize indications and recommendations for HIV preexposure prophylaxis in adolescents and young adults • Describe approaches for successful transition of young adults with HIV into adult primary care HIV practice settings |
| HIV in Women Completed April 23, 2024 | <ul style="list-style-type: none"> • Describe key epidemiologic features of women with HIV in the United States • Summarize contraception options and recommendations for women with HIV • Discuss recommended antiretroviral regimens for women who may become pregnant • Identify conception strategies for heterosexual HIV-serodifferent couples desiring pregnancy • List appropriate steps for evaluation and management of vaginal discharge |
| HIV in Older Adults Completed April 23, 2024 | <ul style="list-style-type: none"> • Recognize age-related and HIV-related changes to the immune systems of people 50 years of age and older • Discuss the interplay of HIV and the aging process within the framework of accelerated and accentuated aging • List recommendations for antiretroviral therapy management in persons 50 years of age and older. • Explain expected virologic and immunologic responses to antiretroviral therapy in persons 50 years of age and older. • Highlight comorbidities that more commonly occur in older adults with HIV |
| HIV and Corrections Completed April 23, 2024 | <ul style="list-style-type: none"> • Explain the difference between prisons and jails • Discuss trends in HIV rates in state and federal prisons • List different types of HIV testing practices conducted in correctional facilities • Describe issues related to HIV medication administration and adherence within correctional facilities • Summarize recommendations for linking persons with HIV to clinical care after release from a correctional facility |
| HIV-2 Infection Completed April 23, 2024 | <ul style="list-style-type: none"> • Contrast HIV-2 and HIV-1 epidemiology, natural history, and pathogenesis • Describe diagnostic testing for HIV-2 • Summarize susceptibility of HIV-2 to antiretroviral medications • Discuss antiretroviral treatment recommendations for persons with HIV-2 • Explain challenges with monitoring after starting antiretroviral therapy for HIV-2 |